730 filings
Page 5 of 37
424B2
yhfiknx
21 Oct 22
Prospectus for primary offering
5:15pm
UPLOAD
jg0u45pjls9lq cm
19 Oct 22
Letter from SEC
12:00am
CORRESP
po5 ohue06dp8
19 Oct 22
Correspondence with SEC
12:00am
8-K
ca3qa51kowv1 l4wn
16 Sep 22
Departure of Directors or Certain Officers
5:15pm
8-K
qcv8hf ehx6
13 Sep 22
Regulation FD Disclosure
8:44am
8-K
24od8r
12 Sep 22
Regulation FD Disclosure
7:34am
8-K
utvp5snx10u03s
2 Aug 22
Aptose Reports Results for the Second Quarter 2022
4:10pm
8-K
nkksfobckm x3
22 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
8-K
kvh6p869vvq z6em
19 Jul 22
Financial Statements and Exhibits
5:53pm
8-K
8s66kuifp9i1traiof
28 Jun 22
Departure of Directors or Certain Officers
3:30pm
8-K
3u8 6azpgslp
27 Jun 22
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
2:29pm
8-K
7js0znylmggdz94api
27 Jun 22
Financial Statements and Exhibits
9:55am
8-K/A
rzf5di8dcuavzsn9jms
6 Jun 22
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
4:51pm
8-K
zkrfebv1q30
2 Jun 22
Aptose Presents Highlights from Corporate Update and KOL Event
5:30pm
8-K
9tc estc7t
31 May 22
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
5:13pm
8-K
7f16zeplinw pc
9 May 22
Aptose Reports Results for the First Quarter 2022
4:30pm
8-K
an6bfy5z3zwsdyy3
4 May 22
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
7:40am